Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer
Cellular Oncology · 2023
DOI: 10.1007/s13402-023-00794-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2023. Verfasst von Yi-Yi Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Zhongshan School of Medicine, Sun Yat- sen University, Guangzhou, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Colorectal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guangdong Basic and Applied Basic Research Foundation of China, Guangzhou Science and Technology Project of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Colorectal cancer (CRC) is one of the most common malignancies worldwide, with dramatically increasing incidence and mortality for decades. However, current therapeutic strategies for CRC, including chemotherapies and immunotherapies, have only demonstrated limited efficacy. Here, we report a novel immune molecule, CD43, that can regulate the tumor immune microenvironment (TIME) and serves as a promising target for CRC immunotherapy. METHODS: The correlation of CD43 expression with CRC patient prognosis was revealed by public data analysis. CD43 knockout (KO) CRC cell lines were generated by CRISPR-Cas9 technology, and a syngenetic murine CRC model was established to investigate the in vivo function of CD43. The TIME was analyzed via immunohistochemical staining, flow cytometry and RNA-seq. Immune functions were investigated by depletion of immune subsets in vivo and T-cell functional assays in vitro, including T-cell priming, cytotoxicity, and chemotaxis experiments. RESULTS: In this study, we found that high expression of CD43 was correlated with poor survival of CRC patients and the limited infiltration of CD8+ T cells in human CRC tissues. Importantly, CD43 expressed on tumor cells, rather than host cells, promoted tumor progression in a syngeneic tumor model. Loss of CD43 facilitated the infiltration of immune cells and immunological memory in the TIME of CRC tumors. Mechanistically, the protumor effect of CD43 depends on T cells, thereby attenuating T-cell-mediated cytotoxicity and cDC1-mediated antigen-specific T-cell activation. Moreover, targeting CD43 synergistically improved PD-L1 blockade immunotherapy for CRC. CONCLUSION: Our findings revealed that targeting tumor-intrinsic CD43 could activate the antitumor immune response and provide particular value for optimized cancer immunotherapy by regulating the TIME in CRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Zhongshan School of Medicine, Sun Yat- sen University, Guangzhou, China.
- Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
- GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, China.
- Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
- Key Laboratory of Tropical Disease Control of the Ministry of Education, Sun Yat-sen University, Guangzhou, China.
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Zhongshan School of Medicine, Sun Yat- sen University, Guangzhou, China. yiwei@gzzoc.com.
Förderung
- Guangdong Basic and Applied Basic Research Foundation of China
- Guangzhou Science and Technology Project of China
- National Natural Science Foundation of China
- National Key R&D Program of China
- Guangdong project
- Grant from MOE Key Laboratory of Gene Function and Regulation
Zitieren
APA
Li, Y. Y., Wang, X. Y., Li, Y., Wang, X. M., Liao, J., Wang, Y. Z., Hong, H., Yi, W., & Chen, J. (2023). Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer. Cellular Oncology. https://doi.org/10.1007/s13402-023-00794-w
Vancouver
Li YY, Wang XY, Li Y, Wang XM, Liao J, Wang YZ, et al. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer. Cellular Oncology. 2023. doi:10.1007/s13402-023-00794-w
BibTeX
@article{Li2023,
author = {Li, Yi-Yi and Wang, Xin-Yu and Li, Yan and Wang, Xiu-Mei and Liao, Jing and Wang, Ying-Zhao and Hong, Hai and Yi, Wei and Chen, Jun},
title = {Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer},
journal = {Cellular Oncology},
year = {2023},
doi = {10.1007/s13402-023-00794-w}
}
EUVIMED